Company Profile

We are a clinical‐​stage biophar­ma­ceu­tical company focused on the devel­opment of Aramchol^™, liver‐​targeted stearoyl‐​coenzyme A desaturase‐​1 (“SCD1ˮ) modulator, a first in class, novel, once‐​daily, oral therapy for the treatment of NASH (Non‐​alcoholic Steatohepatitis).

We believe that our product candidate, Aramchol^™, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that consti­tutes a large unmet medical need.

Galmed’s business has been operating since 2000 under a different group of companies estab­lished in the same year. Galmed Pharmaceuticals Ltd. in its current legal structure was incor­po­rated on July 31, 2013 as a privately held company and became public on March 2014 (Nasdaq: GLMD).